Search ↗

Comparison

BPC-157 vs TB-500

Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, TB-500 is the better documented of the two (preliminary human). That is a statement about the state of the literature, not a recommendation.

BPC-157 TB-500
Class Healing & repair Healing & repair
Evidence Animal models only Preliminary human
Human trials None published ~4
Half-life ~4 hours ~2-3 hours
Reported range 200-500 mcg 2-5 mg
Frequency 1-2x daily, often near the injury site 2x weekly loading, then weekly
Routes Subcutaneous, Oral, Intramuscular Subcutaneous, Intramuscular
FDA approved No No
Research use only Yes Yes
Banned in sport Yes Yes
Studied for Tendon and ligament injury research, Gastrointestinal healing research, Soft tissue repair Soft tissue repair research, Wound healing, Cardiac repair research
Reported side effects Injection-site reactions, Transient nausea, Headache, Dizziness Injection-site reactions, Transient fatigue, Head rush, Mild nausea

BPC-157

BPC-157 is a stable 15-amino-acid sequence derived from body protection compound, a protein found in human gastric juice. Animal work reports accelerated healing across tendon, ligament, muscle, bone and gastrointestinal tissue, with proposed mechanisms including upregulation of VEGF-driven angiogenesis, modulation of the nitric oxide system, and increased fibroblast migration and growth-factor receptor expression. The evidence base is almost entirely rodent. No adequately powered human trial has been published, which is the central fact about this compound and should lead every page about it.

TB-500

TB-500 is the synthetic form of thymosin beta-4, a 43-residue peptide whose principal activity is sequestering G-actin and regulating cytoskeletal assembly. That function underlies its reported effects on cell migration, angiogenesis and wound repair, with the LKKTETQ heptapeptide identified as the active binding region. Human data exists from small trials in dry eye and pressure ulcers; the musculoskeletal claims that drive its popularity rest on animal models.

BPC-157 vs TB-500: common questions

What is the difference between BPC-157 and TB-500?

Both are healing & repair. BPC-157: A synthetic pentadecapeptide derived from a gastric protein, and the most searched compound in the peptide category. TB-500: A synthetic version of thymosin beta-4, the actin-sequestering peptide most often paired with BPC-157.

Which has stronger evidence, BPC-157 or TB-500?

TB-500 has the stronger evidence base (preliminary human, about 4 human studies) compared with BPC-157 (animal models only).

Are BPC-157 and TB-500 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 9941957) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 137525-51-0 ↗ · chemical identity
  5. PubChem compound record (CID 62707662) ↗ · structure, identifiers, synonyms
  6. CAS Registry Number 77591-33-4 ↗ · chemical identity

Published literature

  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res 2019.PubMed 30915550 · doi:10.1007/s00441-019-03016-8
  2. Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.Curr Pharm Des 2018.PubMed 29998800 · doi:10.2174/1381612824666180712110447
  3. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  5. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?.Arthroscopy 2025.PubMed 39265666 · doi:10.1016/j.arthro.2024.09.005
  6. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  7. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  8. Seiwerth S, Brcic L, Vuletic LB, et al.. BPC 157 and blood vessels.Curr Pharm Des 2014.PubMed 23782145 · doi:10.2174/13816128113199990421
  9. Sun HQ, Yin HL. The beta-thymosin enigma.Ann N Y Acad Sci 2007.PubMed 17495248 · doi:10.1196/annals.1415.021
  10. Hannappel E. beta-Thymosins.Ann N Y Acad Sci 2007.PubMed 17468232 · doi:10.1196/annals.1415.018
  11. Fox JE. The platelet cytoskeleton.Thromb Haemost 1993.PubMed 8165606
  12. Gebran S, Romano E, Soyano A. [Biomolecules suppressing myelopoiesis].Acta Cient Venez 1992.PubMed 1343739
  13. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing.Vitam Horm 2016.PubMed 27450738 · doi:10.1016/bs.vh.2016.04.005

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.